


patient	gender	age	tumor size (cm)	Fuhrmann Grade	TNM	metastasis	performance status	MSKCC criteria	HLA-Type	sunitinib pre-treatment	TIL expansion	Tumor cell line
n1	M	59	14	4	pT4N2M1	LN, liver, lung	WHO 0	intermediate	A2	-	yes	yes
n2	M	53	9	2	pT2aNxMx	-	WHO 0	intermediate	-	-	no	no
n3	M	60	11,5	1	cT3cN1M1	LN, lung	WHO 1	unfavorable	-	-	no	no
n4	M	40	7	4	pT3aN2M1	LN, bone, lung, adrenal gland	WHO 1	intermediate	A2/A3	-	yes	yes
n5	M	49	4	3	pT1aNxMx	-	WHO 0	intermediate	-	-	no	no
n6	F	49	10	2	pT3bN0M0	-	WHO 0	n.a.	A2/A3	-	yes	yes
n7	M	65	5	1	pT1bcNxMx	possible lung and mediastinal LN	WHO 0	n.a.	-	-	no	no
n8	F	64	4,5	1	pT1N0M0	-	WHO 0	n.a.	A1/A3	-	yes	yes
n9	F	60	19	4	pT3bN2M0	LN	WHO 1	unfavorable	A11	-	yes	yes
n10	M	65	8	2	pT3aN0M0	para-aortic and lung	WHO 1	intermediate	A2	-	yes	yes
n11	F	78	8	2	pT3aN1M0	-	WHO 0	n.a.	A1/A3	-	yes	no
n12	F	64	9	1	pT3bN0M0	-	WHO 0	n.a.	A1	-	yes	yes
n13	F	67	6	2	pT1pN0cM0	-	WHO 0	n.a.	A2	-	yes	yes
n14	M	54	11	4	pT2N0M0	-	WHO 1	n.a.	A2	-	yes	no
n15	M	55	9	2	pT2N0M1	lung, pleura	WHO 1	intermediate	A11	-	yes	yes
n16	F	62	8	3	pT4N2M1	LN, lung, muscle	WHO 1	unfavorable	A1/A11	-	yes	yes
n17	M	70	13	4	pT3cN2M1	LN	WHO 0	intermediate	A1	-	yes	yes
s1	F	72	8	3	pT4N0M0	-	WHO 0	n.a.	A2	2 cycles suted	yes	yes
s2	M	44	2,3	2	pT2N1M1	skeletal	WHO 2	unfavorable	A1	2 cycles suted	yes	yes
s3	F	52	8	4	cT3pN2M1	LN, liver, skeletal	WHO 0	intermediate	A2	2 cycles suted	yes	yes
s4	M	64	2,5	1	pT1N0M1	skeletal	WHO 1	intermediate	A2/A3/B7	3 cycles suted	yes	yes
s5	M	66	6	3	T1bN0M1	lung	WHO 0	intermediate	A1/A2	3 cycles suted	yes	yes
s6	M	50	3,7	3	pT1aN0M1	lung, skeletal	WHO 1	intermediate	A11	2 cycles suted	yes	yes
s7	M	49	7	3	pT3aN2M1	LN, liver, skeletal	WHO 0	favorable	A1/A2	2 cycles suted	yes	yes
s8	F	57	10	3	pT2N2M1	LN, lung	WHO 1	intermediate	A2	3 cycles suted	yes	yes
s9	M	65	19	4	pT3aN2M1	LN, pleura, thyroid	WHO1	unfavorable	A2/A11	3 cycles suted	yes	yes
s10	F	60	7	4	pT1N2M1	LN, lung, liver	WHO 2	unfavorable	A2	3 cycles suted	yes	yes
s11	V	71	6	?	cT2cN1M1	LN, lung	WHO 2	unfavorable	-	4 cycles suted	no	no
s12	M	70	8	2	pT3bNxM1	lung, adrenal gland	WHO 0	intermediate	A11	3 cycles suted	yes	yes
s13	M	43	4	2	cT1bcNxM1	skeletal,adrenal gland	WHO 1	intermediate	-	3 cycles suted	no	no

**Supplemental Table 1: Patient characteristics in detail**



**Supplemental Figure 1: Tumor digestion leads to a superior fold expansion as compared to TIL outgrowth from tumor fragments.** RCC tissues samples from three different patients (n8, n9 and s7) were split in half and either fragmented (cut into smaller pieces aiming at a size of 1 mm<sup>3</sup>, to obtain each 12 fragments that were placed individually into 24 well plates) or digested as described in the materials & methods section. After 25 days of TIL culture the number of expanded leucocytes was determined individually.